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Abstract 
 
Background: 
Perioperative dexamethasone is associated with attenuation of the postoperative systemic 
inflammatory response and fewer postoperative complications following elective surgery for 
colorectal cancer.   
This study examined the impact of different doses of dexamethasone, given to reduce 
postoperative nausea and vomiting (PONV) after elective colonic resection for cancer, on the 
postoperative Glasgow Prognostic Score (poGPS) and morbidity. 
 
Methods: 
Patients from a single centre were included if they underwent potentially curative resection of 
colonic cancer from 2008 to 2017 (n=480).  Patients received no dexamethasone (209, 44%), 
or either 4mg (166, 35%), or 8mg (105, 21%), intravenously during anaesthesia, at the 
discretion of the anaesthetist.  The postoperative Glasgow Prognostic Score (poGPS) on day 
3 and 4, and complication rate at discharge were recorded. 
 
Results: 
When patients were grouped by surgical approach (open or laparoscopic) and dexamethasone 
dose (0mg, 4mg or 8mg), there was a statistically significant linear trend toward a lower 
postoperative systemic inflammatory response (day 3 poGPS) with the use of minimally 
invasive surgery and higher doses of dexamethasone (p<0.001).  Furthermore, this 
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combination of laparoscopic surgery and higher doses of dexamethasone was significantly 
associated with a lower proportion of postoperative complications (p<0.001).   
At multivariate Cox regression, dexamethasone was not significantly associated with either 
improved or poorer cancer specific or overall survival. 
 
Conclusions: 
Higher doses of perioperative dexamethasone are associated with greater reduction in 
postoperative systemic inflammation and complications following surgery for colonic cancer 
without negative impact on survival.   
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1.0 Introduction 
Long term survival following surgery for colorectal cancer is primarily related to disease 
stage, however postoperative morbidity is also a negative prognostic factor [1].  These 
complications have a high price in terms of both health care costs, and impact on wider 
society, due to prolonged hospital stay and delay in return to function.  
Postoperative complications have been reported to be associated with an exaggerated 
systemic inflammatory response following surgery for colorectal cancer [2].  The acute phase 
marker C-reactive protein (CRP) is increasingly recognised to be a reliable measure of this 
postoperative systemic inflammatory response (SIR) [3].  Postoperative CRP concentrations 
are now considered to be a useful, early surrogate marker for developing postoperative 
complications [4].  In addition, increasing evidence suggests that the postoperative SIR may 
have a causal influence on postoperative complications, and a negative impact on oncologic 
outcomes following surgery for colorectal cancer [5]. 
Corticosteroids are commonly administered at the induction of anaesthesia in colorectal 
surgery for the prevention of postoperative nausea and vomiting (PONV) [6].  A recent meta-
analysis has reported that pre-operative administration of corticosteroids is associated with a 
reduction in the post-operative systemic inflammatory response, measured by CRP, and 
complications following surgery for gastrointestinal cancers [7]. A further recent randomised 
controlled trial (RCT) of perioperative corticosteroids in pancreatic cancer surgery reported a 
reduction in postoperative complications in patients given preoperative steroids [8].  In 
colorectal cancer surgery a recent observational study reported a significant association 
between dexamethasone, administered to reduce risk of PONV, and a reduction in both 
postoperative CRP concentrations and complications [9].   
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Despite this, no study has sought to detect whether a dose response relationship exists 
between perioperative steroids and either the postoperative systemic inflammatory response 
or complications.  Furthermore, some concerns have been raised regarding the possibility of 
increased rates of disease recurrence in patients given perioperative steroids [10].  Therefore, 
the aims of the present study were to examine the impact of varying doses of dexamethasone 
given in the perioperative period to prevent PONV, on the postoperative systemic 
inflammatory response, complications, and survival following elective surgery for colon 
cancer. 
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2.0 Methods 
2.1 Patients: 
This was a retrospective observational study of patients with histologically confirmed colonic 
cancer, undergoing potentially curative resection, at a single centre from March 2008 to June 
2017 were included.  Those excluded from analysis were patients for whom there was no 
available anaesthetic record, those prescribed long term steroids, with diagnosed 
inflammatory conditions, with rectal cancer, who had emergency surgery, or palliative 
resection. 
Each case was discussed at a specialist colorectal oncology multi-disciplinary team prior to 
and following resection.  As described previously, all patients were given venous 
thromboprophylaxis and antibiotic prophylaxis at the induction of anaesthesia.  Patients were 
managed according to a unit standardised perioperative care protocol, including early enteral 
nutrition, early postoperative mobilisation, and no routine nasogastric or peritoneal drainage.  
Patients were given intravenous dexamethasone, either 4mg or 8mg, at the induction of 
anaesthesia, to reduce the risk of significant postoperative nausea and vomiting, at the 
anaesthetic staff’s discretion [9]. 
Patients were reviewed by their own surgical team on each postoperative day.  Serum CRP 
and albumin were obtained from daily blood samples drawn as standard until the patient was 
discharged.  The patient’s surgical team arranged further investigation,  and/or intervention, 
based on their own judgement and were not blind to serum CRP results. 
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2.2 Methods: 
Anonymised clinicopathological data was recorded prospectively in a secure database, and 
was subsequently analysed.  Patient demographics, TNM stage (TNM, 5th ed, AJCC), and in 
particular, factors known to influence the magnitude of the postoperative systemic 
inflammatory response; American Society of Anesthesiology (ASA) grade, body mass index 
(BMI), surgical approach and preoperative systemic inflammation, were recorded [11].  
Retrospective review of anaesthetic records allowed the collection of data relating the use of 
dexamethasone at the induction of anaesthesia.   
Serum concentrations of CRP (mg/L) and were measured using an autoanalyzer (Architect; 
Abbot Diagnostics, Maidenhead, UK) with a lower detectable limit of 0.2 mg/L, as was 
serum albumin (normal range 35-50g/L).  The preoperative modified Glasgow Prognostic 
Score (mGPS: CRP ≤10 mg/L = 0. CRP > 10 mg/L and albumin ≥35 g/L = 1, CRP >10 mg/L 
and albumin <35 g/L = 2), was calculated in patients for whom preoperative serum CRP and 
albumin were available [12].  The validated Postoperative Glasgow Prognostic Score 
(poGPS: CRP ≤150 mg/L = 0; CRP >150 mg/L and albumin ≥25 g/L = 1; CRP >150 mg/L 
and albumin <25 g/L = 2) was calculated on postoperative days 3 and 4 [13].   
Complications were recorded and  the most severe for each patient categorised by its Clavien 
Dindo grade [14]. Infective complications were categorised as described previously [2].  
The study was approved by the West of Scotland Research Ethics Committee, Glasgow, as 
part of surgical audit. 
 
2.3 Statistical analysis: 
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The Chi square test for significance, and Chi square test for trend, were used to compare 
categorical and ordinal data.  Univariate and multivariate binary logistic regression was used 
to characterise preoperative and operative factors associated with postoperative 
complications.  Those variables associated with postoperative complications at a significance 
of p<0.01 were included in backward conditional multivariate model where a two sided p 
value ≤0.05 was considered statistically significant.  A priori subgroup analysis of those 
patients undergoing open and laparoscopic surgery separately was carried out as it is 
recognised to be a significant determinant of the postoperative systemic inflammatory 
response [11].  Univariate and multivariate Cox regression was used to analyse survival data.  
Thirty day mortalities and deaths during the index admission were excluded from analysis. 
On univariate Cox regression, those variables associated with cancer specific (CSS) or 
overall survival (OS) with statistical significance p ≤0.05 were then included in multivariate 
Cox regression.  This multivariate modelling used backward conditional regression where a 
two sided p value ≤0.05 was used as the threshold for statistical significance.  CSS was 
calculated as time from the date of surgery to that of death due to colonic cancer.  Overall 
survival was calculated as time from the date of surgery to death due to any cause.    All 
analyses were carried out using IBM SPSS for Windows (v24, Chicago, IL, USA).           
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3.0 Results 
 
3.1 Patients: 
The study included 480 patients in total, who had undergone surgery for colonic cancer with 
curative intent over the study period.  The majority were female (264, 55%), over 65 years 
old (334, 70%), with node negative disease (297, 62%).  196 patients (41%) had a 
laparoscopic resection with the remainder having open surgery.  166 patients (35%) were 
given 4mg of dexamethasone, 105 patients (21%) were given 8mg of dexamethasone and the 
remainder (209, 44%) did not receive dexamethasone.  Of all included patients, 154 (32%) 
went on to have adjuvant treatment following surgery.  Of all included patients, 182 (38%) 
experienced a postoperative complication, of which 112 (23%) were classed as infective, and 
40 (8%) were Clavien Dindo grade 3-5.  There were 5 (1%) deaths either within 30 
postoperative days or the index admission.  Of all included patients 439 had preoperative 
CRP and albumin measured, allowing calculation of mGPS.  448 patients had CRP and 
albumin measured on postoperative day 3, allowing calculation of poGPS 3, and 375 patients 
had CRP and albumin measured on postoperative day 3, allowing calculation of poGPS 4. 
 
3.2 Impact of dexamethasone in patients undergoing elective colon cancer resection: 
Within the 480 included patients (Table 1) there was a significant association between 
perioperative dexamethasone dose received and patients ASA grade (p=0.007), preoperative 
mGPS (p=0.003), TNM stage (p=0.022), intraoperative blood transfusion (p=0.012), and 
laparoscopic surgery (p<0.001) 
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There was a significant association between perioperative dexamethasone and a lower 
postoperative systemic inflammatory response on postoperative days 3 (poGPS 2; 0mg 27%, 
4mg 13%, 8mg 8%, p<0.001), and 4 (poGPS 2; 0mg 22%, 4mg 13%, 8mg 9%, p=0.007). 
There was a significant association between perioperative dexamethasone and a lower rate of 
postoperative complications (0mg 48%, 4mg 31%, 8mg 29%, p<0.001), and infective 
complications (0mg 30%, 4mg 18%, 8mg 19%, p=0.009), but not Clavien Dindo grade 3-5 
complications (p=0.121) 
 
3.3 Factors associated with the postoperative systemic inflammatory response 
At univariate binary logistic regression (Table 2), males sex (p=0.021), laparoscopic surgery 
(p<0.001), and perioperative dexamethasone (p<0.001) were significantly associated with 
day 3 poGPS.  At multivariate binary logistic regression, laparoscopic surgery (OR 0.53, 95% 
CI 0.35-0.81, p=0.003) and dexamethasone (OR 0.44, 95% CI 0.29-0.66, p<0.001) remained 
independently associated with day 3 poGPS. 
 
3.4 Factors associated with postoperative complications: 
At univariate binary logistic regression (Table 2), male sex (p=0.004), ASA (p=0.007), 
preoperative mGPS (p=0.010), laparoscopic surgery (p<0.001), perioperative dexamethasone 
dose (p<0.001), intraoperative blood transfusion (p=0.013) and day 3 poGPS (p<0.001) were 
significantly associated with postoperative complications.  At multivariate binary logistic 
regression, dexamethasone (OR 0.51, 95% CI 0.32-0.84, p=0.008), and day 3 poGPS (OR 
2.42, 95% CI 1.76-3.33, p<0.001) remained independently associated with postoperative 
complications.   
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3.5 The magnitude of the postoperative systemic inflammatory response and complications: 
When patients were grouped by surgical approach (open or laparoscopic) and dexamethasone 
dose (0mg, 4mg or 8mg), there was a statistically significant linear trend (Table 3) toward a 
lower postoperative systemic inflammatory response (day 3 poGPS) with the use of 
minimally invasive surgery and higher doses of dexamethasone (p<0.001).  Furthermore, this 
combination of laparoscopic surgery and higher doses of dexamethasone was significantly 
associated with a lower proportion of postoperative complications (p<0.001). 
 
3.6 Impact of dexamethasone on survival following elective colon cancer resection: 
There were 136 deaths during the study period, of which 74 were due to colonic cancer.  The 
median follow up for patients alive at the time of censoring was 55 months (range 12-122).  
At multivariate analysis, neither dexamethasone or grouping by surgical approach and 
dexamethasone dose were significantly associated with either improved or poorer cancer 
specific or overall survival (Table 4). 
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4.0 Discussion 
 
The present study reports a possible dose response relationship between attenuation of the 
postoperative systemic inflammatory response measured by the poGPS and postoperative 
complications, through a combination of dexamethasone given at the induction of anaesthesia 
and laparoscopic surgery.   Indeed, when patients were grouped by surgical approach and 
perioperative dexamethasone, there was a linear association between the magnitude of the 
surgical injury, postoperative systemic inflammatory response, and complications.  
Furthermore, despite prior concerns, the present study reports no association between 
dexamethasone and poorer oncologic outcomes. 
Currently corticosteroids are primarily given in the perioperative period to reduce post-
operative nausea and vomiting (PONV) [15].  The recent “Dexamethasone versus standard 
treatment for postoperative nausea and vomiting in gastrointestinal surgery: randomised 
controlled (DREAMS) trial reported a significant reduction in PONV in patients undergoing 
colorectal surgery given 8mg intravenous dexamethasone compared to placebo [6].  
Perioperative steroids have also been shown to reduce postoperative pain, with calls to 
expand their use and proceed with procedure specific dose finding studies in this context 
[16].  A previous propensity score matched study published by our group in patients with 
colorectal cancer reported a significant association between dexamethasone, attenuation of 
the postoperative systemic inflammatory response, and fewer postoperative complications 
[9].  However, the present study moves the debate forward, being to our knowledge the first 
work to report a “dose dependent” relationship between attenuation of the postoperative 
systemic inflammatory response and complications.  A recent Cochrane review reported no 
association between perioperative steroids and wound complications across a variety of 
surgical specialties, however, did not report the relationship with any measures of the 
13 
 
postoperative systemic inflammatory response [17]. Furthermore, two currently recruiting 
randomised controlled trials of perioperative dexamethasone, PADDI 
(ACTRN12614001226695) and PACMAN (NCT03218553), are investigating the effect on 
surgical site infection, and major postoperative complications respectively.  However, neither 
are limited to colorectal surgery, and neither include measures of the postoperative systemic 
inflammatory response in their outcomes.  
The mechanism of action through which dexamethasone, and other corticosteroids, have their 
anti-inflammatory effects have still to be completely elucidated.  With regard to the adaptive 
immune system, amongst other effects, down regulatory effects on lymphoid tissue are 
thought to occur through inhibition of nuclear factor κB (NF- κB) [18]. In relation to the 
innate immune system, increased transcription of lipocortins leads to down-regulation of 
cyclo-oxygenase related pathways, whilst steroids decrease circulating pro-inflammatory 
mediators including IL 6, resulting in an overall lessening of this response [19-20].  Recent 
evidence in healthy volunteers and surgical patients given doses of dexamethasone similar to 
that used to prevent PONV have shown rapid effects on circulating innate immune cells and 
circulating cytokines and may both initially attenuate innate immune responses but then allow 
for later immune activation, suggesting an immunomodulatory role rather than that of 
straightforward immunosuppression [21-22]. 
Laparoscopic surgery is well recognised to be associated with a reduction in the magnitude of 
the postoperative systemic inflammatory response following colorectal surgery [11].  
Furthermore, it has been reported to be associated with fewer postoperative complications 
[13].  Whether this simply relates to the smaller abdominal wounds required, or whether other 
factors such as the use of carbon dioxide for insufflation, or the no-touch isolation technique 
generally used, remains unclear. 
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Although postoperative complications are recognised to have a negative impact on cancer 
specific survival and disease recurrence, the mechanism by which they lead to these poorer 
outcomes is unclear [23].   The creation of a pro-metastatic environment through systemic 
inflammation, both in relation to surgical trauma, and as a consequence of  postoperative 
complications, could be hypothesised to be such a mechanism, allowing metastatic disease 
progression [24].  It could then be hypothesised that a reduction in the magnitude of the 
postoperative systemic inflammatory response may improve long term outcomes following 
surgery for colorectal cancer through direct means and through a reduction in postoperative 
complications, although this could not be demonstrated with statistical significance in the 
present study. 
The main limitation of the present study was its retrospective nature.  The administration of 
dexamethasone, and the use of minimally invasive surgery, was entirely at the discretion of 
the surgical and anaesthetic team, and therefore possible bias exists with regard to individual 
surgeon outcomes.  There were significant differences amongst the patients when grouped by 
dexamethasone dose, specifically with regards to the proportions of patients undergoing open 
or laparoscopic surgery.  However, given that surgical approach is the main confounder of 
postoperative systemic inflammation [25], subgroup analysis was necessary.  Patients who 
underwent open surgery and received 8mg of dexamethasone were an outlier with regard to 
the overall linear relationship, in that they had a relatively high rate of postoperative 
complications.  However, they were the smallest subgroup, which may have impacted the 
analysis.  In addition, patients undergoing rectal cancer surgery were not included as they 
represent a much more heterogeneous group with regards to their surgery, preoperative 
oncology, and anaesthesia.  It is reassuring then, that the results pertaining to long term 
outcome are in keeping with those recently published by a group examining the use of 
dexamethasone in pancreatic cancer surgery [26].    
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5.0 Conclusions 
The present retrospective study in patients undergoing elective surgery for colonic cancer 
reports a possible dose dependent reduction in the postoperative systemic inflammatory 
response, and fewer complications, associated with the combination of laparoscopic surgery 
and dexamethasone.  The use of dexamethasone was not associated with any negative 
prognostic impact. These findings should be assessed in prospective randomised studies to 
allow consideration as to whether dexamethasone should be administered in this group of 
patients for reasons other than purely postoperative nausea and vomiting. 
16 
 
Acknowledgments 
We thank the surgical department and Consultant Colorectal Surgeons of Glasgow Royal 
Infirmary for their input. 
 
 
Conflicts of interest 
None 
 
 
Sources of funding 
None 
  
17 
 
References 
1. Artinyan A, Orcutt ST, Anaya DA, Richardson P, Chen GJ, Berger DH.  Infectious 
postoperative complications decrease long-term survival in patients undergoing curative 
surgery for colorectal cancer.  Ann Surg  2015;261(3):497-505 
2. Platt JJ, Ramanathan ML, Crosbie RA, Anderson JH, McKee RF, Horgan PG, McMillan 
DC.  C-reactive protein as a predictor of postoperative infective complications after curative 
resection in patients with colorectal cancer.  Ann Surg Oncol.  2012;19:4168-4177 
3. Watt DG, Horgan PG, McMillan DC.  Routine clinical markers of the magnitude of the 
systemic inflammatory response after elective operation: a systematic review.  Surgery  
2015;157(2):362-380 
4. Adamina M, Steffen T, Tarantino I, Beutner U, Schmied BM, Warschkow R.  Meta-
analysis of the predictive value of C-reactive protein for infectious complications in 
abdominal surgery.  Br J Surg  2015;102:590-598 
5. McSorley ST, Watt DG, Horgan PG, McMillan DC.  Postoperative systemic inflammatory 
response, complication severity, and survival following surgery for colorectal cancer.  Ann 
Surg Oncol  2016;23(9):2832-2840 
6. Magill L, DREAMS Trial Collaborators and West Midland Research Collaborative.  
Dexamethasone versus standard treatment for postoperative nausea and vomiting in 
gastrointestinal surgery: randomised controlled trial (DREAMS Trial).  Br Med J  
2017;357:j1455 
7. McSorley ST, Horgan PG, McMillan DC.  The impact of preoperative corticosteroids on 
the systemic inflammatory response and postoperative complications following surgery for 
gastrointestinal cancer: a systematic review and meta-analysis.   2016;101:139-150 
18 
 
8. Laaninen M, Sand J, Nordback I, Vasama K, Laukkarinen J.  Perioperative hydrocortisone 
reduces major complications after pancreaticoduodenectomy: a randomized controlled trial.  
Ann Surg  2016;264(5):696-702 
9. McSorley ST, Roxburgh CSD, Horgan PG, McMillan DC.  The Impact of Preoperative 
Dexamethasone on the Magnitude of the Postoperative Systemic Inflammatory Response and 
Complications Following Surgery for Colorectal Cancer. Ann Surg Oncol. 2017 
Aug;24(8):2104-2112 
10. Singh PP, Lemanu DP, Taylor MH, Hill AG.  Association between pre-operative 
glucocorticoids and long-term survival and cancer recurrence after colectomy: follow-up 
analysis of a previously randomized trial.  Br J Anaesth  2014;113(S1):i68-i73 
11. Watt DG, Ramanathan ML, McSorley ST, Walley K, Park JH, Horgan PG, McMillan 
DC. Clinicopathological Determinants of an Elevated Systemic Inflammatory Response 
Following Elective Potentially Curative Resection for Colorectal Cancer. Ann Surg Oncol 
2017;24, 2588-2594. 
12. McMillan DC.  The systemic inflammation-based Glasgow Prognostic Score: a decade of 
experience in patients with cancer.  Cancer Treatment Reviews.  2012;36(5):534-540 
13.  Watt DG, McSorley ST, Park JH, Horgan PG, McMillan DC.  A postoperative systemic 
inflammation score predicts short- and long-term outcomes in patients undergoing surgery for 
colorectal cancer.  Ann Surg Oncol  2017;24(4):1100-1109 
14. Dindo D, Demartines N, Clavien P.  Classification of surgical complications: a new 
proposal with evaluation in a cohort of 6336 patients and results of a survey.  Ann Surg.  
2004;240:205-213 
19 
 
15. Karanicolas PJ, Smith SE, Kanbur B, Davies E, Guyatt GH.  The impact of prophylactic 
dexamethasone on nausea and vomiting after laparoscopic cholecystectomy: a systematic 
review and meta-analysis.  Ann Surg 2008;248(5):751-762 
16. Kehlet H.  Postoperative pain, analgesia, and recovery – bedfellows that cannot be 
ignored.  Pain  2018;159:S11-S16 
17.  Polderman JAW, Farhang-Razi V, Van Dieren S, Kranke P, DeVries J, Hollmann MW, 
Preckel B, Hermanides J. Adverse side effects of dexamethasone in surgical patients. 
Cochrane Database of Systematic Reviews 2018,11:CD011940. DOI: 
10.1002/14651858.CD011940.pub3 
18. Chu CC, Hsing CH, Shieh JP, Chien CC, Ho CM, Wang JJ.  The cellular mechanisms of 
the antiemetic action of dexamethasone and related glucocorticoids against vomiting.  Eur J 
Pharmacol  2014;722:48-54 
19. Rhen T, Cidlowski JA.  Anti-inflammatory action of glucocorticoids – new mechanisms 
for old drugs.  N Engl J Med  2005;353:1711-23 
20. Leung DYM, Bloom JW.  Update on glucocorticoid action and resistance.  J Allergy Clin 
Immunol  2003;111(1):3-22 
21. Bain CR, Draxler DF, Taylor R, Wallace S, Gouldthorpe O, Corcoran TB, Myles PS, 
Medcalf RL, Bozaoglu K.  The early in-vivo effects of a single anti-emetic dose of 
dexamethasone on innate immune cell gene expression and activation in healthy volunteers.  
Anaesthesia 2018;73:955-966 
22. Corcoran T, Paech M, Law D, Muchatuta NA, French M, Ho KM.  Intraoperative 
dexamethasone alters immune cell populations in patients undergoing elective laparoscopic 
gynaecological surgery.  Br J Anaesthesia  2017;119(2):221-230 
20 
 
23. McSorley ST, Horgan PG, McMillan DC.  The impact of the type and severity of 
postoperative complications on long-term outcomes following surgery for colorectal cancer: a 
systematic review and meta-analysis.  Crit Rev Oncol Haematol 2016;97:168-177 
24. McAllister SS, Weinberg RA.  The tumour induced systemic environment as a critical 
regulator of cancer progression and metastasis.  Nat Cell Biol 2014;16(8):717-727 
25. Ramanathan ML, MacKay G, Platt J, Horgan PG, McMillan DC.  The impact of open 
versus laparoscopic resection for colon cancer on c-reactive protein concentrations as a 
predictor of postoperative infective complications.  Ann Surg Oncology.  2015;22(3):938-943 
26. Sandini M, Ruscic KJ, Ferrone CR, Warshaw AL, Qadan M, Eikermann M, Lillemoe 
KD.  Intraoperative dexamethasone decreases infectious complications after 
pancreaticoduodenectomy and is associated with long-term survival in pancreatic cancer. 
Ann Surg Oncol  2018 [epub ahead of print] DOI: https:/doi.org/10.1245/s10434-018-6827-5 
 
 
  
21 
 
Tables and footnotes 
Table 1: Association between clinicopathological characteristics, perioperative factors and 
preoperative dexamethasone in patients undergoing elective surgery for colonic cancer 
Characteristic  Preoperative dexamethasone P 
 No, n (%) 4mg, n (%) 8mg, n (%) 
N  209 (44) 166 (35) 105 (21) - 
Clinicopathological      
Age (years) <65 59 (28) 52 (31) 35 (33) 0.216 
 65-74 82 (39) 66 (40) 42 (40)  
 >74 68 (33) 48 (29) 28 (27)  
Sex  Male 84 (40) 91 (55) 41 (40) 0.655 
 Female 125 (60) 75 (45) 64 (60)  
BMI (kg/m2) <20 12 (6) 10 (6) 3 (3) 0.406 
 20-25 60 (31) 57 (35) 27 (26)  
 26-30 53 (28) 48 (30) 38 (36)  
 >30 67 (35) 47 (29) 37 (35)  
ASA  1 32 (16) 33 (20) 22 (22) 0.007 
 2 89 (43) 74 (45) 51 (50)  
 3 72 (35) 53 (33) 27 (27)  
 4 12 (6) 3 (2) 1 (1)  
Preop mGPS  0 131 (70) 120 (80) 80 (82) 0.003 
 1 17 (9) 14 (9) 10 (10)  
 2 40 (21) 17 (11) 8 (8)  
TNM stage 1 34 (16) 42 (26) 27 (26) 0.022 
 2 91 (44) 60 (37) 43 (41)  
 3 70 (34) 54 (33) 33 (32)  
 4 12 (6) 6 (4) 1 (1)  
Operative      
Approach  Open 161 (77) 77 (47) 40 (39) <0.001 
 Laparoscopic 47 (23) 86 (53) 63 (61)  
Surgery >4h Yes 29 (14) 42 (26) 19 (19) 0.156 
 No 174 (86) 121 (74) 83 (81)  
Intraop blood transfusion Yes 17 (10) 4 (3) 2 (3) 0.012 
 No 152 (90) 126 (97) 68 (97)  
Postoperative      
poGPS 3 0 83 (42) 98 (65) 72 (74) <0.001 
 1 62 (31) 33 (22) 17 (18)  
 2 55 (28) 20 (13) 8 (8)  
poGPS 4 0 113 (62) 85 (69) 53 (76) 0.008 
 1 28 (16) 23 (18) 11 (16)  
 2 40 (22) 16 (13) 6 (9)  
Any complication Yes 100 (48) 51 (31) 31 (29) <0.001 
 No 107 (52) 114 (69) 73 (71)  
Infective complication Yes 63 (30) 29 (18) 20 (19) 0.009 
 No 114 (70) 136 (82) 84 (81)  
22 
 
Clavien Dindo 3-5 Yes 21 (10) 14 (9) 5 (5) 0.121 
 No 186 (90) 150 (91) 99 (95)  
BMI  body mass index. ASA American Society of Anesthesiologists score.  POD postoperative day. CRP C-
reactive protein, mGPS preoperative modified Glasgow Prognostic score (0 = CRP<10mg/L, 1 = CRP≥10mg/L 
and albumin ≥35g/L, 2 = CRP≥10mg/L and albumin <35g/L), poGPS postoperative Glasgow Prognostic Score 
(0 = CRP<150mg/L, 1 = CRP>150mg/L and albumin >25g/L, 2 = CRP>150mg/L and albumin<25g/L)  
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Table 2: Impact of preoperative dexamethasone dose on postoperative systemic inflammation 
and complications following surgery for colonic cancer, univariate and multivariate binary 
logistic regression 
poGPS 3 ≥1 Univariate OR 
(95% CI) 
P Multivariate OR 
(95% CI) 
P 
Age 0.96 (0.76-1.22) 0.754 - - 
Male Sex 1.56 (1.07-2.27) 0.021 1.49 (1.00-2.21) 0.051 
BMI 1.15 (0.93-1.42) 0.188 - - 
ASA 1.08 (0.84-1.37) 0.574 - - 
mGPS 1.28 (0.98-1.67) 0.073 - - 
Laparoscopic 0.41 (0.28-0.61) <0.001 0.53 (0.35-0.81) 0.003 
Dexamethasone (any dose) 0.35 (0.24-0.52) <0.001 0.44 (0.29-0.66) <0.001 
Surgery >4h 0.78 (0.48-1.27) 0.320 - - 
Transfusion 1.63 (0.70-3.83) 0.259 - - 
TNM stage 1.13 (0.90-1.42) 0.286 - - 
Complications Univariate OR 
(95% CI) 
P Multivariate OR 
(95% CI) 
P 
Age 1.15 (0.92-1.43) 0.214 - - 
Male Sex 1.66 (1.17-2.36) 0.004 - 0.182 
BMI 0.95 (0.78-1.14) 0.568 - - 
ASA 1.36 (1.09-1.71) 0.007 - 0.686 
mGPS 1.38 (1.08-1.77) 0.010 - 0.370 
Laparoscopic 0.43 (0.29-0.62) <0.001 - 0.749 
Dexamethasone (any dose) 0.45 (0.31-0.66) <0.001 0.51 (0.32-0.84) 0.008 
Surgery >4h 1.21 (0.78-1.88) 0.396 - - 
Transfusion 3.06 (1.26-7.43) 0.013 - 0.162 
TNM stage 0.93 (0.75-1.15) 0.495 - - 
poGPS 3 2.56 (2.01-3.27) <0.001 2.42 (1.76-3.33) <0.001 
OR Odds Ratio, CI Confidence Interval , BMI  body mass index. ASA American Society of Anesthesiologists 
score.  POD postoperative day. CRP C-reactive protein, mGPS preoperative modified Glasgow Prognostic score 
(0 = CRP<10mg/L, 1 = CRP≥10mg/L and albumin ≥35g/L, 2 = CRP≥10mg/L and albumin <35g/L), poGPS 
postoperative Glasgow Prognostic Score (0 = CRP<150mg/L, 1 = CRP>150mg/L and albumin >25g/L, 2 = 
CRP>150mg/L and albumin<25g/L)  
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Table 3: Association between attenuation of the magnitude of the postoperative systemic 
inflammatory response and postoperative complications in patients undergoing elective 
surgery for colonic cancer 
Characteristic  Open Lap Open Open Lap Lap P 
 0mg Dex 0mg Dex 4mg Dex 8mg Dex 4mg Dex 8mg Dex 
  n (%) n (%) n (%) n (%) n (%) n (%)  
N  161 (34) 46 (10) 76 (16) 39 (8) 84 (18) 66 (14) - 
poGPS 3 0 61 (39) 21 (49) 41 (58) 23 (62) 53 (70) 50 (82) <0.001 
 1 49 (31) 13 (30) 15 (21) 8 (22) 18 (24) 9 (15)  
 2 46 (30) 9 (21) 15 (21) 6 (16) 5 (7) 2 (3)  
Complication Yes 81 (50) 19 (41) 28 (37) 19 (48) 22 (26) 13 (19) <0.001 
 No 80 (50) 27 (59) 48 (63) 20 (52) 62 (74) 53 (81)  
BMI  body mass index. ASA American Society of Anesthesiologists score.  POD postoperative day. CRP C-
reactive protein, mGPS preoperative modified Glasgow Prognostic score (0 = CRP<10mg/L, 1 = CRP≥10mg/L 
and albumin ≥35g/L, 2 = CRP≥10mg/L and albumin <35g/L), poGPS postoperative Glasgow Prognostic Score 
(0 = CRP<150mg/L, 1 = CRP>150mg/L and albumin >25g/L, 2 = CRP>150mg/L and albumin<25g/L)  
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Table 4: Impact of preoperative dexamethasone dose, postoperative systemic inflammation 
and complications on survival following surgery for colonic cancer, univariate and 
multivariate survival analysis (Feb 19) 
Survival Variable Univariate HR (95% 
CI) 
P Multivariate HR 
(95% CI) 
P 
CSS Age 1.50 (1.06-2.17) 0.024 1.62 (1.12-2.33) 0.010 
 Male Sex 1.66 (0.95-2.99) 0.075 - - 
 ASA 1.18 (0.84-1.67) 0.336 - - 
 mGPS 1.43 (1.01-2.02) 0.041 - 0.467 
 Laparoscopic 0.79 (0.45-1.39) 0.416 - - 
 Dexamethasone (any dose) 0.66 (0.38-1.12) 0.126 - - 
 Lap/Dex inflammation group 0.89 (0.77-1.04) 0.132 - - 
 TNM stage 2.57 (1.79-3.69) <0.001 2.77 (1.89-4.06) <0.001 
 poGPS 3 1.29 (0.93-1.79) 0.132 - - 
 Complication 1.64 (0.97-2.79) 0.065 - - 
      
OS Age 1.76 (1.36-2.27) <0.001 1.57 (1.19-2.09) 0.002 
 Male Sex 1.50 (1.01-2.21) 0.043 - 0.132 
 ASA 1.54 (1.20-1.97) 0.001 1.35 (1.01-1.79) 0.040 
 mGPS 1.60 (1.26-2.03) <0.001 1.34 (1.05-1.71) 0.021 
 Laparoscopic 0.72 (0.47-1.08) 0.113 - - 
 Dexamethasone (any dose) 0.62 (0.41-0.91) 0.016 - 0.918 
 Lap/Dex inflammation group 0.87 (0.78-0.97) 0.013 - 0.678 
 TNM stage 1.76 (1.37-2.26) <0.001 1.75 (1.34-2.28) <0.001 
 poGPS 3 1.23 (0.97-1.57) 0.095 - - 
 Complication 1.58 (1.09-2.31) 0.017 1.49 (0.99-2.23) 0.055 
HR Hazard Ratio, CI Confidence Interval , DSS  disease specific survival, OS overall survival, mGPS modified 
Glasgow Prognostic Score, POD postoperative day  
 
 
 
